SCHEMBL2926918

SCHEMBL2926918

CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(C)(=O)=O)c3)nn2c1-c1ccncc1

nearest known ligand 0.53

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 14/20 0.53
PIK3CB P42338 6/20 0.53
PIK3CD O00329 6/20 0.53
PIK3CG P48736 6/20 0.53
MTOR P42345 8/20 0.48
AKT1 P31749 5/20 0.48
AKT2 P31751 1/20 0.47
AKT3 Q9Y243 1/20 0.47
FYN P06241 3/20 0.44
CSNK1D P48730 1/20 0.42
CSNK1E P49674 1/20 0.42
PIK3C3 Q8NEB9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2917989 0.88 PIK3CA (0.65) PIK3CAPIK3CBPIK3CDPIK3CGMTOR
SCHEMBL2924265 0.87 PIK3CA (0.52) PIK3CAPIK3CBPIK3CDPIK3CGMTOR
SCHEMBL2920507 0.87 PIK3CA (0.51) PIK3CAPIK3CBPIK3CDPIK3CGMTOR
SCHEMBL2946540 0.85 PIK3CA (0.49) PIK3CAPIK3CBPIK3CDPIK3CGMTOR
SCHEMBL2919456 0.85 PIK3CA (0.58) PIK3CAPIK3CBPIK3CDPIK3CGMTOR
SCHEMBL2927119 0.83 AKT1 (0.48) PIK3CAPIK3CBPIK3CDPIK3CGMTOR
SCHEMBL2923640 0.79 PIK3CA (0.50) PIK3CAPIK3CBPIK3CDPIK3CGMTOR
SCHEMBL2918526 0.77 PIK3CA (0.76) PIK3CAPIK3CBPIK3CDPIK3CGMTOR
SCHEMBL2923077 0.76 PIK3CA (0.47) PIK3CAPIK3CBPIK3CDPIK3CGMTOR
SCHEMBL2923806 0.75 PIK3CA (0.47) PIK3CAPIK3CBPIK3CDPIK3CGMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090163489-A1 Inhibitors of PI3 kinase AMGEN INC. 2009-06-25 US claimed
US-7820665-B2 Imidazopyridazine inhibitors of PI3 kinase for cancer treatment AMGEN INC. (US) 2010-10-26 US disclosed
US-7820665-B2 Imidazopyridazine inhibitors of PI3 kinase for cancer treatment AMGEN INC. (US) 2010-10-26 US disclosed
US-7820665-B2 Imidazopyridazine inhibitors of PI3 kinase for cancer treatment AMGEN INC. (US) 2010-10-26 US disclosed
EP-2231661-A1 INHIBITORS OF PI3 KINASE Amgen, Inc. (US) 2010-09-29 EP disclosed
WO-2009085230-A1 INHIBITORS OF PI3 KINASE AMGEN INC. (US) 2009-07-09 WO disclosed
WO-2009085230-A1 INHIBITORS OF PI3 KINASE AMGEN INC. (US) 2009-07-09 WO disclosed
US-20090163489-A1 Inhibitors of PI3 kinase AMGEN INC. 2009-06-25 US disclosed
US-20090163489-A1 Inhibitors of PI3 kinase AMGEN INC. 2009-06-25 US disclosed
US-20090163489-A1 Inhibitors of PI3 kinase AMGEN INC. 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163489-A1 Inhibitors of PI3 kinase PIK3CA, PIK3CD, PIK3CG PIK3CA 1/4885PIK3CB 4/4885PIK3CD 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.